Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 16/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12373517 | 0.92 | S1PR1 (0.44) | S1PR1CYP2C19ALDH1A1MMP13 | |
| SCHEMBL12373548 | 0.92 | S1PR1 (0.49) | S1PR1CYP2C19ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL12373467 | 0.91 | S1PR1 (0.46) | S1PR1ALDH1A1SMN1; SMN2MMP13LMNA | |
| SCHEMBL12373521 | 0.91 | S1PR1 (0.45) | S1PR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL12373495 | 0.89 | S1PR1 (0.43) | S1PR1SMN1; SMN2ADAMTS4 | |
| SCHEMBL4119410 | 0.89 | CNR1 (0.47) | S1PR1ALDH1A1MMP13 | |
| SCHEMBL12373519 | 0.89 | S1PR1 (0.49) | S1PR1CYP2C19ALDH1A1SMN1; SMN2CYP3A4 | |
| SCHEMBL12373701 | 0.89 | S1PR1 (0.42) | S1PR1CYP2C19ALDH1A1ADAMTS4MMP13 | |
| SCHEMBL12373649 | 0.89 | S1PR1 (0.42) | S1PR1CYP2C19MMP13 | |
| SCHEMBL12373499 | 0.88 | S1PR1 (0.41) | S1PR1MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994204-B2 | Binding inhibitor of sphingosine-1-phosphate | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-08-09 | — | — | US | disclosed |
| US-7994204-B2 | Binding inhibitor of sphingosine-1-phosphate | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20090182144-A1 | BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090182144-A1 | BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182144-A1 | BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885CYP2C19 3489/4885ALDH1A1 2969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.